Targeted radiation combo shows promise for older AML patients
NCT ID NCT06802523
First seen Jan 07, 2026 · Last updated Apr 24, 2026 · Updated 17 times
Summary
This early-phase trial tests a new combination of three drugs for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The drugs include a targeted radiation therapy (lintuzumab-Ac-225), a BCL-2 inhibitor (venetoclax), and a hypomethylating agent (ASTX-727). The goal is to find the safest dose and see if the combination improves remission rates. About 53 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale University Cancer Center LAO
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.